




# Non Small Cell Lung Cancer (NSCLC)




Stage IV/Metastatic - 2nd Line - Immunotherapy



Progressed on Immunotherapy

[ECOG-ACRIN-  
EA5191](#)  
Randomized  
Phase II Trial of  
Cabozantinib &  
Cabozantinib +  
Nivolumab vs  
Standard  
Chemotherapy in  
Previously Treated  
Non-Squamous  
NSCLC  
PI: Neal  
Sponsor:  
ECOG-ACRIN

## KEY

-  Pending
-  Open for Enrollment
-  Observational Study

-  Optional Path
-  [Link](#) Trial Posting
-  Enrollment on Hold

-  Extension Study
-  Immunotherapy